BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1344 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Conditions
- Advanced Solid MalignanciesNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 252
- Registration Number
- NCT07223047
- Locations
- 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States
🇺🇸Local Institution - 0007, Salt Lake City, Utah, United States
🇺🇸Local Institution - 0011, Fairfax, Virginia, United States
A Study to Evaluate the Effect of KarXT on Urological Safety
- Conditions
- Schizophrenia
- Interventions
- Drug: Xanomeline/trospium chloride
- First Posted Date
- 2025-10-28
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT07221877
- Locations
- 🇺🇸
Local Institution - 0017, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0007, Bellflower, California, United States
🇺🇸Local Institution - 0009, Culver City, California, United States
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 690
- Registration Number
- NCT07221149
- Locations
- 🇺🇸
Local Institution - 0284, Phoenix, Arizona, United States
🇺🇸Local Institution - 0240, Los Angeles, California, United States
🇺🇸Local Institution - 0277, Orange, California, United States
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Conditions
- Untreated, Unresectable, or Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 990
- Registration Number
- NCT07221357
- Locations
- 🇺🇸
Local Institution - 0263, Los Angeles, California, United States
🇺🇸Local Institution - 0345, Orange, California, United States
🇺🇸Local Institution - 0317, Sacramento, California, United States
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT07215975
- Locations
- 🇸🇦
Prince Muhammad bin Nasser Hospital, Jizan, Saudi Arabia
- Prev
- 1
- 2
- 3
- 4
- 5
- 301
- Next
News
FDA Proposes Streamlined Approval Pathway to Accelerate Biosimilar Drug Development
The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.
CAR-T Therapies from Cabaletta Bio and Bristol Myers Squibb Achieve Complete Remissions in Severe Inflammatory Muscle Disease
Experimental CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients with severe inflammatory muscle disease, according to dual clinical trial results presented this week.
Evotec Receives $25M Milestone Payment from Bristol Myers Squibb for Neuroscience Partnership Progress
Evotec received a $25 million payment from Bristol Myers Squibb for achieving scientific progress in their strategic neuroscience partnership focused on neurodegenerative diseases.
Bristol Myers Squibb Reports Promising CAR-T Cell Therapy Results for Three Autoimmune Diseases
Bristol Myers Squibb presented Phase 1 data from 71 patients showing its CD19 NEX-T CAR-T therapy achieved immune reset across three severe autoimmune diseases with 94% of patients remaining off immunosuppressive therapy.
Biokin Receives Record $250 Million ADC Milestone Payment from Bristol Myers Squibb
Biokin secured a $250 million milestone payment from Bristol Myers Squibb in October 2025, marking the largest antibody-drug conjugate milestone payment among Chinese innovative drug out-licensing deals.
Flagship Pioneering Launches Expedition Medicines with $50M Investment in AI-Driven Covalent Drug Discovery
Flagship Pioneering has launched Expedition Medicines with a $50 million investment, focusing on AI-driven drug discovery for cancer and immune diseases using covalent chemistry principles.
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
iMDx Appoints Marketing VP to Spearhead Commercial Launch of Transplant Rejection Diagnostic
Insight Molecular Diagnostics (iMDx) has appointed Steven Tahmooressi as Vice President of Marketing to lead the commercial launch of its GraftAssureDx transplant rejection diagnostic kit.
Bristol Myers Squibb and Lilly Showcase Major Oncology Data at ESMO 2025
Bristol Myers Squibb will present data from over 50 studies at ESMO 2025, including first-in-class results from izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific ADC that received FDA Breakthrough Therapy designation for EGFR-mutated NSCLC.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.